Det svenska bioteknikbolaget Aptahem AB (publ) (”Aptahem” eller ”Bolaget”) utvecklar RNA-baserade lä...
Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...
I april 2025 lämnade EFSA (Europeiska myndigheten för livsmedelssäkerhet) ett positivt vetenskaplig...
Nettoomsättningen för det första kvartalet uppgick till 8,2 MEURO (10,9), vilket motsvarade en minsk...
Organic sales decline of 9% y-o-y EBIT margin of 5.
No real progress in Q1 Market to turn positive in '25e, according to report Turnaround delayed, '25e...
STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products app...
The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 202...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 16 maj 2025 att Bolaget mottagit en ny orde...
After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, w...
Redeye provides an update following CLS’s Q1 2025 report.
Redeye comments on Lytix Biopharma’s first quarter review of 2025.
Redeye provides an update following Paxman’s Q1 2025 report.
Gullberg & Jansson redovisade minskad nettoomsättning och EBIT i det första kvartalet.
Portfolio rebalancing and weak market behind PW We lower '25e-'27e EBIT by 31-22% on lower sales We ...
HydrogenPro published the Company’s interim report for the first quarter of 2025 on May 15, 2025.
Sales SEK 54m (ABGSCe 55m), EBIT -4m (ABGSCe -7m) Market conditions remain soft, anticipates weaker ...
Redeye briefly comments on Dala Energi’s Q1 report, which presented no real surprises.
Voi, som är VNV Globals näst största innehav, kom med en stark Q1-rapport.
